BioNTech Shots Trigger More Antibodies Than Sinovac, SCMP Says
This article is for subscribers only.
The BioNTech SE Covid-19 vaccine triggered “substantially higher” levels of antibodies compared to the Chinese-made Sinovac jab, the South China Morning Post reported Saturday, citing a study by the University of Hong Kong.
The results suggested some recipients of the Sinovac vaccine may need a third shot, the newspaper said, citing lead researcher Benjamin Cowling. The epidemiologist led the government-commissioned study that tracked antibody responses of 1,000 vaccinated people.